Incyte

Pemazyre (pemigatinib) is a small-molecule fibroblast growth factor receptor 2 (FGFR2) inhibitor developed by Incyte for the treatment of unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangement. The program is currently in Phase 3 development under the trial identifier INCB 54828-302, formally known as FIGHT-302, which is an open-label, randomized, active-controlled, multicenter study comparing pemigatinib monotherapy to gemcitabine plus cisplatin chemotherapy as first-line treatment. Cholangiocarcinoma is a rare biliary tract malignancy with limited treatment options, and FGFR2 rearrangements represent a validated molecular subset representing approximately 10–15% of cases. The FIGHT-302 trial represents a pivotal efficacy and safety evaluation against the current standard-of-care chemotherapy regimen. Regulatory status across major markets remains not yet disclosed, though the program is actively recruiting and enrolling patients. This represents a targeted approach to an orphan indication with significant unmet medical need.

Cholangiocarcinoma is a highly aggressive biliary tract malignancy with poor prognosis and limited therapeutic options. Patients with unresectable or metastatic disease historically have had median overall survival of 8–12 months with gemcitabine-cisplatin chemotherapy, the current standard of care. FGFR2 rearrangements occur in approximately 10–15% of cholangiocarcinoma cases and represent a validated oncogenic driver, making this population amenable to targeted therapy. The FIGHT-302 trial directly compares a selective FGFR2 inhibitor to chemotherapy, potentially establishing a new standard of care for this molecularly defined subset. Success in this indication would address a significant unmet medical need in a rare disease with high mortality and morbidity. The commercial opportunity is substantial within the orphan oncology space, particularly given the precision medicine positioning and potential for companion diagnostic-driven patient selection. Competitive programs targeting FGFR2 in cholangiocarcinoma include BGJ398 (BridgeBio), TAS-120 (Taiho), and E7090 (Eisai), indicating active development in this space. Regulatory approval would likely confer orphan drug designation and associated exclusivity benefits.

Drug Class: Selective fibroblast growth factor receptor 2 (FGFR2) inhibitor.

Modality: Small-molecule kinase inhibitor.

Route of Administration: Oral (tablet formulations: 4.5 mg, 9 mg, 13.5 mg).

Target: FGFR2 (fibroblast growth factor receptor 2); mechanism of action not yet disclosed in available facts.

Formulations in Trial: Pemazyre tablets combined with gemcitabine 1000 mg powder for solution for infusion and Cisplatin Ebewe 1 mg/ml concentrate for infusion solution in the comparator arm.

• Gemcitabine: nucleoside analog, FDA-approved antimetabolite chemotherapy agent used in multiple solid tumors; approved in Australia (PBS codes 4439P, 7246J; sponsors EUGIA PHARMA and Pfizer Australia) and United States (ANDA078460, ANDA090644 via Teva and Eurohlth).
• Cisplatin: platinum-based chemotherapy agent, widely approved globally as standard-of-care component in biliary and other solid tumors.

Related Therapies: Competing FGFR2 inhibitors in development include BGJ398 (Phase 3, BridgeBio), TAS-120 (Phase 2, Taiho), and E7090 (Phase 2, Eisai).

FDA (United States): Regulatory status not yet disclosed.

EMA (European Union): Regulatory status not yet disclosed.

PMDA (Japan): Regulatory status not yet disclosed.

NMPA (China): Gemcitabine is listed in clinical trials in China (NCT01762150, NCT01764828, NCT01915134, NCT02299765, NCT03503604, NCT03601975, NCT03629925, NCT03656536, NCT06326736, NCT06904573); pemigatinib regulatory status in China not yet disclosed.

Australia: Gemcitabine (component of comparator arm) is approved and listed on PBS with codes 4439P and 7246J; sponsors include EUGIA PHARMA (Australia) Pty Ltd and Pfizer Australia Pty Ltd.

Pemigatinib Approval History: Not yet disclosed in available facts.

Strategic Positioning: Incyte's pemigatinib represents a precision oncology approach to a rare, high-mortality malignancy. The Phase 3 FIGHT-302 trial directly compares monotherapy to the current standard-of-care chemotherapy doublet, a design that could establish a new treatment paradigm if efficacy is demonstrated with improved tolerability.

Competitive Implications: BridgeBio's BGJ398 is the primary Phase 3 competitor; however, pemigatinib's active-controlled design against chemotherapy (rather than placebo) may provide stronger clinical evidence for regulatory approval and clinical adoption. Earlier-stage programs (TAS-120, E7090) and combination approaches (immunotherapy + chemotherapy) suggest the field is exploring multiple strategies, but Phase 3 data will be decisive.

Unmet Need: FGFR2-rearranged cholangiocarcinoma represents approximately 10–15% of cases with historically poor outcomes on chemotherapy alone. A selective FGFR2 inhibitor with improved efficacy and tolerability would address a significant unmet need in this orphan indication.

Expected Catalysts: Primary efficacy and safety data from FIGHT-302 (timing not yet disclosed); regulatory submissions to FDA, EMA, and other agencies; potential companion diagnostic co-development for FGFR2 rearrangement detection.

Patent and Exclusivity: Orphan drug designation likely upon approval, conferring 7 years of market exclusivity in the United States and 10 years in the European Union.